Metipranolol pp 106-120 | Cite as

Therapeutic Efficacy of Metipranolol Eye Drops 0.3% Versus Timolol Eye Drops 0.25%

A Double-blind Cross-over Study
  • H. Bleckmann
  • T. Pham Duy
  • O. Grajewski
Conference paper


Since the introduction of β-sympathicolytics in the treatment of elevated intraocular pressure a great number of studies on β-receptor blocking agents dealing with the dynamics of the aqueous humour have been conducted. Ever since the pressure reducing effect was first described in 1970 [1], timolol represents the most widely used β-blocking agent. Timolol is to be classified along with the noncardioselective β-blocking agents, i. e. responsible for the blockade both at the cardial β-1-receptors and at the extra-cardial β-2-receptors of the bronchi and vessels. The newly developed β-blocking agent metipranolol demonstrates slight β-blocking equipotent doses to inhibit isoproterinol tachycardia compared with propranolol. It exhibits very slight sympathomimetic properties and, measured by the elevation of the fibrillation threshold in electrically stimulated rabbits hearts [2], it shows extremely slight membrane-stabilizing properties. The slight β-stimulating property (intrinsic sympathicomimetic activity) both of metipranolol and timolol as well as their slight cardioselectivity already indicate that both drugs are contraindicated in patients with obstructive airways diseases. Relevant studies on the action of non-cardioselective β-blocking agents with and without this effect on the airway resistance [3] and in patients with small airways disease [4] have already been presented. A first clinical study on the action of metipranolol in glaucomatous eyes was published in 1982 [5]. On the basis of the comparison with timolol with regard to maximum reductions in intraocular pressure after single medication with mean value and calculation of range of diffusion, the authors concluded that the action of metipranolol and timolol on intraocular pressure in glaucoma patients is about equal. Studies are also available on the topical anaesthetising effect of metipranolol on corneal sensitivity [6].


Intraocular Pressure Obstructive Airway Disease Elevated Intraocular Pressure Small Airway Disease Heart Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hall, R., Robin, R. D., Share, N.: A new potent β–adrenergic block agent, β–morpholine–4–β–b–butylamine–2–hydroxypropoxy) 1–2–5. thiodiazole hydrogen maleate. Proc. can. Fed. Biol. Soc. 13, 33 – 39 (1970).Google Scholar
  2. 2.
    Bartsch, W., Sponer, G., Dietmann, K.: Experiments in animals on the pharmakological effects of Metipranolol in comparison with Propranolol and Pindolol. Drug Res. 27, 2247–2426 (1977).Google Scholar
  3. 3.
    Bleckmann, H., Dorow, P.: Die Wirkung von Timolol-und PindololAugentropfen auf den intraokularen Druck und Atemwegswiderstand. In: Medikamentöse Glaukomtherapie (Krieglstein, G. H., Leydhecker, W., eds.), pp. 151–157. München: Bergmann. 1982.CrossRefGoogle Scholar
  4. 4.
    Dorow, P., Bleckmann, H.: Die Wirkung von Timolol- und PindololAugentropfen auf die großen und kleinen Atemwege bei Patienten mit einer small-air-ways-disease. In: Medikamentöse Glaukomtherapie (Krieglstein, G. K., Leydhecker, W., eds.), pp. 158–162. München: Bergmann. 1982.Google Scholar
  5. 5.
    Merté, H.-J., Mertz, M., Stryz, J.: Augendruck unter MetipranololEinwirkung. In: Medikamentöse Glaukomtherapie (Krieglstein, G. K., Leydhecker, W., eds.), pp. 189–193. München: Bèrgmann. 1982.CrossRefGoogle Scholar
  6. 6.
    Draeger, J., Buhr-Unger, H., Winter, R.: Die Wirkung von Beta-Rezeptoren-Blockern auf die Hornhautsensibilität. In: Medikamentöse Glaukomtherapie (Krieglstein, G. K., Leydhecker, W., eds.), pp. 195–199. München: Bergmann. 1982.CrossRefGoogle Scholar
  7. 7.
    Krieglstein, G. K.: Langzeituntersuchung zur augendrucksenkenden Wirkung von Timolol-Augentropfen. Klin. Mbl. Augenheilk. 175, 627–633 (1979).PubMedGoogle Scholar
  8. 8.
    Radius, R. L., Diamond, G. R., Pollak, K., Langham, M. E.: Timolol — A new drug for management of chronic simple glaucoma. Arch. Ophthalmol. 96, 1003–1006 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    Ritch, R., Hargett, N. A., Podos, S. M.: The effect of 1.5% Timolol — an aleate on intraocular pressure. Acta ophthalmol. 56, 6–11 (1978).Google Scholar
  10. 10.
    Moss, A. P., Rich, R., Hargett, N. A., Kohn, A. N., Smith, H., Podos, S. M.: A comparison of the effects of Timolol and Epinephrine on intraocular pressure. Am. J. Ophthalmol 86, 489–495 (1978).PubMedGoogle Scholar
  11. 11.
    Merté, H.-J., Merkle, W.: Timolol-Augentropfen in der Glaukomtherapie. Ergebnisse einer Langzeitstudie. Klin. Mbl. Augenheilk. 177, 562–571 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1984

Authors and Affiliations

  • H. Bleckmann
    • 1
  • T. Pham Duy
    • 2
  • O. Grajewski
    • 2
  1. 1.Universitäts-Augenklinik des Klinikums CharlottenburgFreie Universität BerlinBerlinGermany
  2. 2.University Eye Clinic, Clinical Center CharlottenburgFree University BerlinGermany

Personalised recommendations